Ireland

The Health Products Regulatory Authority (HPRA) is the competent authority responsible for the regulation of medicines, medical devices, in vitro diagnostics, and related health products in Ireland. The HPRA operates under a framework established by the Health (Pricing and Supply of Medical Goods) Act 2013, the Medicinal Products (Control of Placing on the Market) Regulations 2007, and aligned European Union legislation, including Regulation (EU) 2017/745 (MDR) for medical devices and Regulation (EU) 2017/746 (IVDR) for in vitro diagnostics. As an EU Member State, Ireland participates fully in the centralised procedure administered by the European Medicines Agency (EMA), the mutual recognition procedure (MRP), and the decentralised procedure (DCP) for pharmaceuticals. Products authorised through the EMA centralised procedure are automatically valid in Ireland, while nationally authorised products require direct submission to the HPRA. Medical devices and diagnostics must bear CE marking in accordance with applicable EU regulations before being placed on the Irish market, and economic operators must register on the European database on medical devices (EUDAMED).

Submissions to the HPRA for national marketing authorisations must follow the Common Technical Document (CTD) format, consistent with ICH guidelines and EU requirements. A locally established EU or European Economic Area (EEA) qualified person responsible for pharmacovigilance (QPPV) is mandatory for pharmaceutical products, and a legal representative established within the EU or EEA is required for medical device manufacturers based outside the Union. Ireland has adopted EU Medical Device Regulation (MDR) and IVDR transition timelines, including phased implementation deadlines extended by EU legislative amendments through 2027 and 2028 for legacy devices. The HPRA has invested significantly in post-Brexit adaptation measures, given Ireland's role as a key regulatory hub for multinational pharmaceutical and medical technology companies, and participates actively in joint scientific consultations and the European Health Data Space initiative. Notified body services for medical device conformity assessment are not provided domestically, so Irish manufacturers typically engage EU-recognised notified bodies in other Member States.

Public procurement of health products in Ireland is primarily coordinated through the Health Service Executive (HSE), the statutory body responsible for delivering health and social care services on behalf of the state. The HSE operates a centralised procurement function through the National Procurement Office (NPO), which negotiates and manages national framework agreements and contracts for medicines, medical devices, diagnostics, and digital health solutions across the public health system. The Department of Health sets overarching policy and funding priorities, while the HSE NPO conducts competitive tender processes in accordance with EU public procurement directives, particularly Directive 2014/24/EU on public procurement, transposed into Irish law via the European Union (Award of Public Authority Contracts) Regulations 2016. Pharmaceuticals reimbursed under public schemes, including the General Medical Services (GMS) scheme and the Drug Payment Scheme, are subject to pricing negotiations managed by the HSE in line with the Health (Pricing and Supply of Medical Goods) Act 2013. The National Centre for Pharmacoeconomics (NCPE) conducts health technology assessments (HTA) to inform reimbursement decisions, with Ireland also participating in EU-level joint clinical assessments under Regulation (EU) 2021/2282 on HTA, which became applicable from January 2025 for oncology and advanced therapy medicinal products.

The private healthcare sector in Ireland represents a significant parallel market, with a substantial proportion of the population holding private health insurance through providers such as VHI Healthcare, Laya Healthcare, and Irish Life Health. Procurement in the private sector is largely decentralised, with individual private hospitals, clinics, and group purchasing organisations negotiating directly with suppliers. Ireland is a high-income country and does not typically access donor-funded procurement channels such as UNICEF Supply Division, the Global Fund, USAID, or Gavi, which are generally reserved for low and middle-income country contexts. There are no formal local manufacturing preference policies mandated within Irish public procurement; however, Enterprise Ireland and IDA Ireland actively support the domestic pharmaceutical and medical technology manufacturing sectors, which are among the most significant in Europe by export value. Sustainability and social value considerations are increasingly integrated into HSE procurement frameworks, consistent with national policy objectives under the National Public Procurement Policy Framework.